At the news
? MIXEDIMPACT 6/10 424B5 filed Jul 14, 2026 at 17:01 ET
Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceeds of ~$516M to fund R&D for its RAS/MAPK pipeline. The filing also discloses encouraging updated Phase 1 data for lead candidate ERAS-0015, showing a 57% uORR8wk in 2L KRAS G12X PDAC at the 32mg RDE dose. The combination of dilutive financing and positive clinical data creates a mixed signal for the stock.
- Offering of 31,428,572 shares at $17.50 per share, raising $550M in gross proceeds (~$516M net)
- Underwriters have a 30-day option to purchase an additional 4,714,285 shares
- Post-offering shares outstanding: 342,235,460 (or 346,949,745 if overallotment exercised)
- New investors face immediate dilution of $14.84 per share (85% of offering price)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access